The material, dubbed NOC-900, was synthesized through a deceptively simple two-step process of hydrothermal treatment followed by high-temperature calcination. What makes it special is not the recipe but the architecture it inherits. Covalent organic frameworks, or COFs, are crystalline lattices built entirely from light elements, stitched together by strong covalent bonds into porous, ordered structures. When such a framework is carbonized, much of that order collapses, but a chemical memory persists: nitrogen atoms remain embedded within the graphite-like carbon network in well-defined bonding configurations. In NOC-900, the dominant configuration is what the researchers call graphite-N-C₃, a nitrogen atom bonded to three carbon atoms within the graphitic lattice, sitting at the edge of the carbon planes like a single impurity atom in an otherwise perfect crystal.

That tiny structural detail turns out to be the whole story. When NOC-900 was added to water containing levofloxacin along with peroxymonosulfate, or PMS, a common oxidizing salt used in advanced oxidation processes, the antibiotic all but disappeared. Within sixty minutes, 97.6 percent of the levofloxacin had been removed. Even more impressive, the catalyst kept working: after five consecutive use-and-regeneration cycles, it still destroyed more than 80 percent of the pollutant, a level of durability that many metal-based catalysts struggle to match.

The system also shrugged off conditions that would cripple lesser catalysts. Real wastewater is a chemical minefield, full of dissolved salts, varying acidity, and competing organic matter. Yet the NOC-900/PMS pair maintained outstanding degradation performance across a pH range stretching from 3.16 to 10.50, and it continued to function in complex water matrices laced with ionic interference. For engineers dreaming of industrial deployment, that robustness matters as much as raw speed, because a catalyst that only works in ultrapure laboratory water is a catalyst that will never clean a real river.

But the central question the study set out to answer was mechanistic: which part of this complicated carbon material actually does the chemistry? Carbon catalysts are notoriously messy, a patchwork of defects, edges, oxygen groups, and nitrogen dopants, and pinpointing the true active site has long frustrated the field. Through a battery of characterization techniques, including X-ray photoelectron spectroscopy to map nitrogen species, electron paramagnetic resonance to spy on reactive intermediates, and quenching experiments with selective scavengers such as furfuryl alcohol, tert-butanol, and p-benzoquinone, the researchers converged on a clear verdict. The graphite-N-C₃ sites are intimately responsible for the system’s signature move: the highly selective production of singlet oxygen.

Singlet oxygen is an unusual weapon in the oxidation arsenal. Unlike hydroxyl radicals or sulfate radicals, which are brute-force, short-lived, and indiscriminate, singlet oxygen is a non-radical, electrophilic species that attacks electron-rich organic molecules with surgical selectivity. That selectivity explains why the NOC-900/PMS system performs so well in real water: radicals would be squandered instantly on chloride ions, bicarbonate, and natural organic matter, while singlet oxygen largely ignores these distractions and goes after the antibiotic. The non-radical pathway also means the catalyst does not depend on metal centers cycling through oxidation states, which is why no cobalt, iron, or manganese leaching complicates the picture. It is catalysis by geometry and electronics alone.

The team did not stop at destruction. Using high-performance liquid chromatography coupled with mass spectrometry, they tracked the intermediate molecules produced as levofloxacin broke apart, mapped the bonds that were cleaved first, and proposed plausible degradation pathways. Critically, they also assessed toxicity along the way, and the news was reassuring: most of the intermediates formed during degradation were more environmentally benign than the parent antibiotic. In other words, the process does not merely convert one invisible pollutant into a nastier one, a pitfall that has undermined other advanced oxidation schemes, but genuinely defuses the molecule’s biological threat as it dismantles it.

The choice of a COF precursor is what gives this approach its conceptual punch. Because COFs are built from molecular building blocks, chemists can, in principle, design the nitrogen environment of the resulting carbon before it ever exists, choosing monomers that place pyridinic, pyrrolic, or graphitic nitrogen exactly where they want it. NOC-900 demonstrates that this design philosophy works for environmental catalysis: the graphite-N-C₃ motif, inherited from the framework’s atomic precision, survives carbonization and becomes the engine of PMS activation. Previous work has shown COF-derived carbons carrying cobalt particles or other metal complexes activating PMS for levofloxacin degradation; this study proves the metal can be left out entirely.

The broader implications ripple outward in several directions. For water treatment, a durable, wide-pH, salt-tolerant, metal-free catalyst addresses many of the practical objections to peroxymonosulfate-based advanced oxidation, from secondary metal contamination to sensitivity to water chemistry. For catalysis science, the study adds a precise entry to the still-incomplete catalog of which nitrogen configurations in carbon do what, sharpening the field’s ability to move from empirical materials screening to rational design. And for the growing literature on non-radical oxidation, it supplies another well-documented case in which singlet oxygen, generated selectively at a defined site, outperforms the radical free-for-all that dominated the field for decades.

There remain, of course, the usual distances between a laboratory beaker and a municipal treatment tank: catalyst synthesis at scale, PMS dosing economics, and long-term performance under continuous flow all await demonstration. But the foundations laid here are solid. By showing that a single nitrogen bonding motif in a carbon lattice can choreograph the selective birth of singlet oxygen and the near-total destruction of a fluoroquinolone antibiotic, Huang and Zhou have turned an abstract materials-chemistry question into a concrete blueprint. The next generation of pollution-fighting carbons may well be designed atom by atom before a single gram of catalyst is ever made.

Subject of Research: Metal-free COF-derived carbon catalysts with graphite-N-C₃ sites activating peroxymonosulfate to degrade levofloxacin via singlet oxygen

Article Title: Mechanistic Insights into Antibiotic Degradation by Covalent Organic Framework-Derived Carbon: Role of Graphite-N-C3 Active Sites

Article References: Mechanistic Insights into Antibiotic Degradation by Covalent Organic Framework-Derived Carbon: Role of Graphite-N-C3 Active Sites. (n.d.). https://doi.org/10.1007/s10562-026-05543-w

Image Credits: AI Generated

DOI: 10.1007/s10562-026-05543-w

Keywords: covalent organic frameworks, peroxymonosulfate, levofloxacin, singlet oxygen, graphitic nitrogen, water treatment, advanced oxidation processes, non-radical oxidation, carbon catalysts, antibiotic pollution, degradation intermediates, toxicity assessment

The design tackles a fundamental tension in wound care. Photothermal therapy, in which light-absorbing nanoparticles heat tissue enough to rupture bacterial membranes, is a powerful antibacterial tool, but the same heat can destroy the delicate growth factors and proteins needed for tissue repair. The researchers solved this by building a material in which heat is not a side effect but a control signal: it triggers the hydrogel to shrink, and that shrinkage itself becomes the mechanism that times and delivers the drugs.

The hydrogel backbone is a copolymer network of gelatin methacryloyl (GelMA), N-isopropylacrylamide (NIPAM), and N-acryloyl glycinamide (NAGA), crosslinked in seconds by 395 nm ultraviolet light. GelMA contributes cell-adhesive motifs that bind integrin receptors on fibroblasts and endothelial cells, supporting proliferation and new blood vessel growth. NAGA was added to counter the brittleness of GelMA; through dense hydrogen bonding it toughens the network, and its polymer form exhibits an upper critical solution temperature that complements the lower critical solution temperature of roughly 32 degrees Celsius displayed by PNIPAM. This dual thermoresponsive architecture gives the material finer control over contraction than single-transition systems.

Embedded in this network are the true workhorses: core-shell nanoparticles made of magnesium coated with polydopamine and conjugated with the fluoroquinolone antibiotic levofloxacin. X-ray photoelectron spectroscopy revealed a striking chemical detail, an interfacial magnesium-fluorine bond that anchors the drug to the particle surface. That bond is acid-sensitive, which matters because infected wounds are typically more acidic than healthy tissue. In the acidic, irradiated environment of an early infection, polydopamine degrades and levofloxacin pours out to halt bacterial DNA replication; as conditions later neutralize, release slows to a sustained trickle of magnesium ions suited to regeneration rather than killing.

The light-triggered mechanics are equally precise. Under 808 nm near-infrared irradiation at 2.0 watts per square centimeter, the polydopamine nanoparticles heat the hydrogel to roughly 45 to 48 degrees Celsius within minutes, pushing it past its phase-transition temperature of about 34 degrees. The network collapses, shrinking in volume by more than 35 percent, and this contraction mechanically drives out the payload. The team quantified the link rigorously: Pearson correlation analysis showed that early-stage release increments of both levofloxacin and magnesium tracked volume shrinkage with coefficients of determination above 0.95. At body temperature without light, passive leakage stayed below 5 percent over 24 hours, meaning the dressing keeps its cargo locked until commanded otherwise.

That command proved devastating to bacteria. Against Escherichia coli and Staphylococcus aureus, the illuminated composite hydrogel reduced viable colony counts by factors of 332 and 212 respectively, far outperforming free antibiotic or heat alone. Scanning electron micrographs showed collapsed membranes and leaked intracellular contents, evidence of the dual mechanism in which photothermal heating disrupts bacterial envelopes while released levofloxacin blocks replication. Crystal violet assays revealed the same hierarchy against biofilms, the slimy bacterial fortresses that chronically resist both immune clearance and antibiotics. The authors note that combining physical and chemical killing may also reduce the selection pressure that drives antibiotic resistance, allowing effective treatment at lower drug doses.

Beyond sterilization, the material actively reshapes the wound’s immunological and vascular landscape. Sustained magnesium release pushed inflammatory M1 macrophages toward the healing-associated M2 phenotype, an effect amplified by mild photothermal stimulation, while polydopamine mopped up the reactive oxygen species that would otherwise sabotage angiogenic signaling. Under oxidative stress mimicking a pathological wound bed, endothelial cells treated with the illuminated hydrogel showed near-complete ROS clearance, robust proliferation, and markedly enhanced tube formation and migration. Macrophage migration reached 86.7 percent within 24 hours, the highest of any tested condition, supporting a swift transition from inflammation to tissue building.

The in vivo results were the most striking. In rats with Staphylococcus aureus-infected full-thickness skin defects, the precursor solution was injected into the wound bed and gelled in place under brief ultraviolet exposure, then irradiated on three consecutive days. Thermal imaging confirmed the hydrogel reached approximately 47 degrees at the wound surface, while histology and TUNEL staining showed no thermal injury to the surrounding tissue. Bacterial burden in the wounds fell roughly 27-fold compared with untreated controls. Wound area shrank by 57 percent at day 3, 73 percent at day 7, and 98.4 percent by day 14, with the hydrogel degrading almost completely in step with tissue regrowth.

Microscopic analysis of healed tissue told the deeper story of why the treated wounds fared better. The MPLG group showed continuous epidermis, the lowest scar index, and well-aligned, densely packed collagen fibers. Immunofluorescence revealed a shift from M1 to M2 macrophage markers, elevated CD31 signaling new blood vessel formation, increased Ki67-driven proliferation, and a maturing collagen profile in which strong type I collagen replaced the provisional type III network. Blood counts, serum chemistry, hemolysis rates, and organ histology all remained normal, indicating the material and its light treatment are well tolerated systemically.

The authors are candid about the road to the clinic. Deep ultraviolet gelation penetrates less than a centimeter of tissue, a limitation for irregular or heavily exuding wounds, and the long-term safety of repeated near-infrared heating in diabetic or ischemic wounds remains unproven. Scaling the multistep nanoparticle synthesis under good manufacturing practice will also demand careful batch control. Still, the modular concept, a dressing that physically pulls wound edges together while releasing the right drug at the right moment, could extend beyond skin to burns and diabetic ulcers, marking a shift from dressings that merely protect wounds to materials that actively run the healing program.

Subject of Research: A near-infrared-responsive contractile hydrogel with core-shell nanoparticles for programmed antibacterial and pro-angiogenic wound healing

Article Title: Contractile hydrogel with NIR-induced spatiotemporally programmed release from core-shell nanoparticles for integrated antibacterial and pro-angiogenic healing

Article References: Zhang, M. J., Song, J., Song, X., Zhang, A., XI, H., & Xin, L. (2026). Contractile hydrogel with NIR-induced spatiotemporally programmed release from core-shell nanoparticles for integrated antibacterial and pro-angiogenic healing. Materials Today Bio, 41, Article 103713. https://doi.org/10.1016/j.mtbio.2026.103713

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103713

Keywords: hydrogel, wound healing, photothermal therapy, near-infrared, levofloxacin, polydopamine, magnesium ions, antibacterial, biofilm, angiogenesis, macrophage polarization, drug release

Helicobacter pylori infects an estimated half of the world’s population and remains highly prevalent across the Eastern Mediterranean region. The bacterium colonizes the gastric mucosa, where it drives chronic inflammation and, in a subset of those infected, progresses to peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma, or adenocarcinoma of the stomach. Eradicating the organism is therefore not merely a matter of relieving dyspepsia; it is a recognized cancer-prevention strategy. Yet the standard triple therapy that dominated H. pylori treatment for decades, a proton pump inhibitor combined with clarithromycin and amoxicillin, has been losing ground worldwide as clarithromycin resistance has climbed, and in Syria the decline has been compounded by antibiotic misuse, disrupted healthcare infrastructure, and limited access to diagnostic resources.

When clarithromycin-based regimens fail or cannot be relied upon, clinicians frequently turn to levofloxacin, a fluoroquinolone antibiotic, as the backbone of alternative combinations. Two such combinations were tested in this trial. The concomitant regimen delivers a proton pump inhibitor, levofloxacin, amoxicillin, and a fourth agent simultaneously for the full 14 days, so the patient takes all drugs at once throughout the treatment period. The sequential regimen splits the therapy into phases: one antibiotic pairing is given first, followed by a second pairing, with the theoretical rationale that an initial phase of amoxicillin reduces bacterial load and damages cell walls in a way that may improve the effectiveness of the subsequent phase while limiting the window in which resistance can emerge.

Sequential therapy has been promoted in some settings as a way to sidestep clarithromycin resistance, and it has been studied extensively in Europe and Asia, but it had never been formally evaluated in Syrian patients. The researchers, led by Marouf Alhalabi of Damascus Hospital together with colleagues at Ibn Al-Nafees Hospital and the Syrian Board in Gastroenterology, designed a single-center, prospective, open-label, randomized superiority trial to answer the question directly under local conditions. The trial was prospectively registered on ClinicalTrials.gov as NCT06065267 on October 3, 2023, and received ethics approval from the Damascus Hospital and Ibn Al-Nafees Ethics Committee under approval number 41/23.

The study enrolled 150 adults with histologically confirmed H. pylori infection, all of whom had never previously received eradication therapy. Participants were assigned equally, 75 to each arm, to either the concomitant or the sequential levofloxacin-based regimen, each lasting 14 days. The primary outcome was eradication success, confirmed by a negative stool antigen test performed six weeks after the completion of therapy, a timing chosen to allow residual bacterial antigen to clear and to avoid false-positive results. The analysis followed the intention-to-treat principle, meaning every randomized patient was counted in the group to which they were assigned regardless of whether they completed the full course, an approach that preserves the real-world validity of the comparison by accounting for dropouts and imperfect adherence.

The numbers told a story of near-equal performance. Concomitant therapy eradicated the infection in 63 of 75 patients, an intention-to-treat rate of 84 percent, while sequential therapy succeeded in 61 of 75, or 81.3 percent. The absolute risk difference was 2.7 percentage points, with a 95 percent confidence interval spanning from minus 9.4 to 14.8, and the comparison yielded a p value of 0.83 with an odds ratio of 1.20, corresponding to a confidence interval of 0.516 to 2.81. In plain terms, the data provide no evidence that one regimen outperforms the other, and the confidence interval is wide enough that a modest advantage in either direction cannot be excluded. The authors were careful to state that the absence of a statistically significant difference does not establish equivalence or non-inferiority, a distinction that matters in clinical trial interpretation: proving two treatments equal requires a trial designed and powered for that purpose, which this superiority trial was not.

Both regimens were generally well tolerated, an important consideration given that eradication therapy requires patients to take multiple medications daily for two weeks. Nausea was the most frequently reported adverse event in both groups, followed by anorexia, headache, a persistent bitter taste, and skin rash. There was no significant difference in the frequency of adverse events between the two arms, suggesting that the added complexity of the sequential schedule does not buy any tolerability advantage. Baseline characteristics of the two groups were comparable, reducing the likelihood that imbalances in age, sex, or disease profile skewed the outcome.

The findings arrive against a backdrop of genuine clinical constraint. In settings where culture and susceptibility testing are unavailable, clinicians must prescribe empirically, choosing regimens based on regional resistance data and local experience rather than on the resistance profile of an individual patient’s infection. Syria’s healthcare system has been strained by years of conflict and economic crisis, and the authors note that susceptibility-guided therapy and many of the internationally recommended first-line regimens may simply be unavailable. In that context, levofloxacin-based empirical therapy remains in use, and the question of which levofloxacin-based strategy to choose is not academic. The trial suggests that when such therapy is required, the simpler concomitant regimen may offer practical advantages: a single, uniform dosing schedule for 14 days is easier to explain, easier to follow, and less prone to the confusion that phased regimens can introduce, with no measurable cost in effectiveness.

The moderate eradication rates observed in both arms, in the low-to-mid 80 percent range, also serve as a reminder that levofloxacin resistance itself is a growing problem in many regions, and that no empirical regimen can be assumed to work indefinitely. The authors emphasize that these findings should be interpreted in light of local resistance patterns and healthcare limitations, and they call for further multi-center studies that incorporate antimicrobial susceptibility testing. Such studies would allow clinicians to match therapy to the actual resistance profile of circulating H. pylori strains, an approach that international guidelines increasingly favor but that remains aspirational in much of the Eastern Mediterranean.

For the broader field, the trial adds a data point from a population that is rarely represented in H. pylori treatment literature. Most eradication trials are conducted in East Asia, Europe, or North America, where resistance patterns, drug availability, and patient populations differ substantially from those in conflict-affected or resource-limited settings. Demonstrating that a straightforward four-drug concomitant regimen achieves roughly 84 percent eradication in treatment-naïve Syrian patients, and that a more complex sequential schedule offers nothing extra, gives local clinicians an evidence-based reason to favor simplicity. As antibiotic resistance continues to erode the effectiveness of legacy regimens worldwide, trials like this one, grounded in the realities of a specific healthcare environment rather than in idealized conditions, are becoming an essential complement to guideline committees’ recommendations.

Subject of Research: A randomized trial comparing levofloxacin-based concomitant and sequential therapies for Helicobacter pylori eradication in treatment-naïve Syrian patients.

Article Title: Levofloxacin-based concomitant versus sequential therapy for Helicobacter pylori eradication in treatment-naïve Syrian patients: a randomized trial showing no superiority of sequential therapy

Article References: Alhalabi, M., Alshiekh, H. A., Sheikh Alhara, A. A., Ismail, A. A., Shehab, W., & Osamah, W. (2026). Levofloxacin-based concomitant versus sequential therapy for Helicobacter pylori eradication in treatment-naïve Syrian patients: a randomized trial showing no superiority of sequential therapy. Gut Pathogens. https://doi.org/10.1186/s13099-026-00881-x

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00881-x

Keywords: Helicobacter pylori, levofloxacin, concomitant therapy, sequential therapy, eradication therapy, antibiotic resistance, randomized clinical trial, Syria, gastroenterology, stool antigen test, fluoroquinolone, clinical trial